FGF2 Rescued Cisplatin-Injured Granulosa Cells through the NRF2-Autophagy Pathway

Int J Mol Sci. 2023 Sep 18;24(18):14215. doi: 10.3390/ijms241814215.

Abstract

Premature ovarian failure (POF) is a complicated disorder related to the apoptosis of granulosa cells. The incidence of chemotherapy-associated POF is rising dramatically owing to the increasing proportion of cancer in adolescents. According to previous studies, oxidative stress caused by chemotherapeutic agents plays an important role in the development of POF. However, the exact effects of nuclear factor-erythroid 2-related factor2 (NRF2), a pivotal anti-oxidative factor, are still unknown in chemotherapy-associated POF. Firstly, we manipulated NRF2 expressions on a genetic or pharmaceutical level in cisplatin-injured granulosa cell models. The results indicate that the increasing NRF2 in cisplatin-injured cells was just compensatory and not enough to resist the accumulated stress. Upregulation of NRF2 could protect granulosa cells against cisplatin via elevating autophagic level by using an autophagic activator (rapamycin) and inhibitor (chloroquine). Additionally, exogenous FGF2 exerted a protective role by increasing NRF2 expression and promoting its nuclear translocation. Meanwhile, the results in cisplatin-POF mice models were consistent with what was found in injured cells. In conclusion, our research proved that FGF2 rescued cisplatin-injured granulosa cells through the NRF2-autophagy pathway and might provide a possible alternative treatment choice by targeting NRF2 for POF patients who are intolerant or unsuitable to FGF2.

Keywords: FGF2; NRF2; POF; autophagy; chemotherapy.

MeSH terms

  • Animals
  • Apoptosis
  • Autophagy
  • Cisplatin / adverse effects
  • Female
  • Fibroblast Growth Factor 2 / metabolism
  • Granulosa Cells / metabolism
  • Humans
  • Menopause, Premature*
  • Mice
  • NF-E2-Related Factor 2 / genetics
  • NF-E2-Related Factor 2 / metabolism
  • Primary Ovarian Insufficiency* / chemically induced
  • Primary Ovarian Insufficiency* / drug therapy
  • Primary Ovarian Insufficiency* / metabolism

Substances

  • Cisplatin
  • Fibroblast Growth Factor 2
  • NF-E2-Related Factor 2